Basilea Pharmaceutica (OTCMKTS:BPMUF) and Novavax (NASDAQ:NVAX) Head-To-Head Comparison

Novavax (NASDAQ:NVAX) and Basilea Pharmaceutica (OTCMKTS:BPMUF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Risk and Volatility

Novavax has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500. Comparatively, Basilea Pharmaceutica has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500.

Valuation and Earnings

This table compares Novavax and Basilea Pharmaceutica”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12 billion	1.38	$440.30 million	($0.58)	-16.31
Basilea Pharmaceutica	$280.43 million	2.83	$48.57 million	N/A	N/A

Novavax has higher revenue and earnings than Basilea Pharmaceutica.

Institutional & Insider Ownership

53.0% of Novavax shares are owned by institutional investors. 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Novavax and Basilea Pharmaceutica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Basilea Pharmaceutica	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and target prices for Novavax and Basilea Pharmaceutica, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3	1	5	0	2.22
Basilea Pharmaceutica	0	1	0	0	2.00

Novavax currently has a consensus target price of $13.00, suggesting a potential upside of 37.42%. Given Novavax’s stronger consensus rating and higher probable upside, equities analysts clearly believe Novavax is more favorable than Basilea Pharmaceutica.

Summary

Novavax beats Basilea Pharmaceutica on 9 of the 12 factors compared between the two stocks.

About Novavax

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.